MK-677 side effects: the blood-sugar problem and a cardiac flag

Because MK-677 has a real, multi-trial human record, its side effects are unusually well documented for a “research” compound — and they’re more than cosmetic. The headline isn’t the water retention everyone mentions; it’s what the drug does to blood sugar, and one serious cardiac signal. For the full efficacy context, see the MK-677 evidence monograph.

The one that matters most: blood sugar

Across multiple trials, MK-677 raised fasting blood glucose and reduced insulin sensitivity. In healthy elderly subjects, four weeks of 25 mg moved fasting glucose from 5.4 to 6.8 mmol/L — into the impaired range.^[1] In the 2-year older-adult trial, fasting glucose rose and insulin sensitivity fell.^[2] In obese men, a glucose tolerance test showed impaired glucose homeostasis at both 2 and 8 weeks.^[3]This is a predictable consequence of sustained GH elevation, and it’s the reason MK-677 is a poor fit for anyone with prediabetes, diabetes, or metabolic-syndrome risk.

Appetite and water retention

Because MK-677 mimics ghrelin — the hunger hormone — increased appetite is expected, and was the most frequent side effect in the 2-year trial, though it “subsided in a few months.”^[2] The other common effects were transient, mild lower-extremity edema (fluid retention) and muscle pain.^[2] The edema reflects GH’s known fluid-retaining effect; it’s usually mild but is worth watching in anyone with blood-pressure or cardiac concerns — which connects to the more serious signal below.

The serious one: a cardiac safety signal

The IGF-1 itself is a double-edged sword

MK-677’s whole mechanism is pushing IGF-1 up — often to supraphysiologic levels (a 60–73% rise sustained over a year in one trial).^[2] That is the intended effect, but chronically elevated IGF-1 is exactly the kind of long-term exposure whose safety nobody has characterized for this use. It’s a reason the lack of long-term outcome data matters, not just an academic footnote.

What wasn’t consistent

For honesty: not every signal replicated. The 2-year trial reported a small rise in cortisol, while several shorter trials found cortisol unchanged — so that one is uncertain.^[2] And widely-repeated claims of pronounced lethargy or drowsiness are not characterized in these controlled trial abstracts; treat them as anecdotal rather than established.

The honest bottom line

MK-677’s side-effect profile is the quiet reason its hype should be discounted. The reliable problems are metabolic — higher fasting glucose and lower insulin sensitivity in trial after trial — plus appetite, fluid retention, and a serious congestive-heart-failure signal that stopped one trial outright.^[1][4] None of that is disqualifying for a carefully monitored, low-risk adult, but it is exactly why MK-677 belongs with a clinician tracking glucose and cardiovascular status — not in a stack assembled from a forum. See also the dosage guide and MK-677 vs sermorelin.